Cross‐Reactive Skin Eruption with Both Carbamazepine and Oxcarbazepine
- 1 January 1993
- Vol. 34 (1) , 163-165
- https://doi.org/10.1111/j.1528-1157.1993.tb02392.x
Abstract
Oxcarbazepine (OCBZ), a 10-keto derivative of carbamazepine (CBZ) has been reported to have a similar range of efficacy and fewer unwanted effects than CBZ since it is a prodrug for the monohydroxy derivative (MHD). A cross-reactivity of only 1 in 4 has been reported between OCBZ and CBZ. For these reasons, we tried OCBZ with 3 consecutive patients with poorly controlled epilepsy who had had a therapeutic response to CBZ but in whom CBZ was discontinued because of serious skin reaction. Each patient had a similar skin response after exposure to only 600-900 mg OCBZ, which suggests a need to practice caution when substituting OCBZ for CBZ in patients known to have serious skin reaction to CBZ.Keywords
This publication has 8 references indexed in Scilit:
- Allergic Rash Due to Antiepileptic Drugs: Clinical Features and ManagementEpilepsia, 1991
- Human Safety of LamotrigineEpilepsia, 1991
- Pharmacokinetics of Anti-Epileptic Drugs and their Clinical SignificanceBehavioural Neurology, 1990
- Oxcarbazepine in MonotherapyBehavioural Neurology, 1990
- Oxcabazepine (®Trileptal) in Anti-Epileptic PolytherapyBehavioural Neurology, 1990
- A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsyEpilepsy Research, 1989
- Oxcarbazepine (GP 47.680): A Possible Alternative to Carbamazepine?Epilepsia, 1987
- Comparison of oxcarbazepine and carbamazepine: a double-blind studyEpilepsy Research, 1987